Immunovant Inc
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2018 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | |
| – | – | – | +110.0% | +4,652.4% | -87.4% | +53.2% | +19.7% | +63.2% | +8.5% | |
| – | – | – | +432.3% | +170.3% | +81.9% | -5.7% | +27.3% | +20.4% | +12.6% | |
| – | – | – | +340.5% | +181.9% | +84.7% | -5.7% | – | – | – | |
| – | – | – | – | -5.0% | +231.6% | -171.7% | – | -557.1% | – | |
| – | -100.0% | – | -40.4% | +577.4% | +21.0% | -22.4% | +82.7% | +110.8% | -98.9% | |
| – | – | – | -40.4% | +577.4% | +21.0% | -22.4% | +82.7% | +110.8% | -98.9% | |
| – | – | +0.0% | -96.0% | +38,520,500.0% | -48.1% | -64.6% | – | – | – | |
| – | – | – | +0.0% | -108.4% | -100.0% | – | – | – | – | |
| – | -99.7% | +10,848.9% | +313.0% | +160.7% | -47.8% | -64.6% | +566.5% | -3.8% | +31.1% | |
| – | -95.3% | +2,049.2% | +1,239.8% | +220.1% | -68.7% | -225.2% | – | -69.6% | +139.3% | |
| – | – | – | – | – | – | – | – | – | – |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.